ArticleOpen forum infectious diseases2026
Parallel Declines in Human Papillomavirus 6/11-Related Disease Incidences: A National Study of Anogenital Warts and Recurrent Respiratory Papillomatosis in Norway.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anogenital warts and recurrent respiratory papillomatosis are conditions caused by human papillomavirus (HPV) types 6/11 that can be prevented by vaccination. We analyzed Norwegian national registry data (2010-2023) to assess the impact of the 4-valent HPV vaccine introduced in 2009. Anogenital warts incidence among females aged 15-29 decreased significantly from 1120.0 to 280.6 per 100 000 (annual percentage change: -10.3%), paralleling a sharp decline in recurrent respiratory papillomatosis from 3.7 to 0.6 per 100 000 (annual percentage change: -11.3%). These results strongly support vaccination impact in reducing the burden of HPV 6/11-related diseases, suggesting successful interruption of transmission pathways and substantial population-level protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.